Comparative Pharmacology
Head-to-head clinical analysis: LANORINAL versus RAUVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANORINAL versus RAUVAL.
LANORINAL vs RAUVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LANORINAL is a combination product containing acetaminophen, which inhibits cyclooxygenase (COX) enzymes and modulates cannabinoid receptors via its metabolite AM404; and butalbital, a barbiturate that enhances GABA-A receptor activity, producing sedative and anxiolytic effects.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
1-2 mg intravenously or intramuscularly every 2-4 hours as needed for pain.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in hepatic impairment.
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Renal: 30-50% unchanged; fecal/biliary: 50-70% as metabolites.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Category C
Category C
Antihypertensive
Antihypertensive